Rapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice

Abstract

Rapamycin is a potent immunosuppressive drug currently used mainly for rejection prophylaxis in renal transplantation. The aim of this study was to determine the effect of rapamycin treatment on the development of nephritis in lupus-prone New Zealand Black/White F₁ (NZB/W F₁) mice. Twelve-week-old female NZB/W F₁ mice were treated with rapamycin (3 mg/kg body weight) or saline once daily by oral gavage for 20 weeks. The severity of nephritis was assessed by clinical and biochemical parameters, renal histology, immunohistochemistry and gene expression studies. Rapamycin treatment markedly reduced proteinuria, improved renal function, decreased serum anti–double stranded DNA antibody levels and diminished splenomegaly. Kidney sections from saline-treated mice showed marked mesangial proliferation, tubular dilation with protein cast deposition and interstitial inflammatory cell infiltration. Rapamycin-treated mice had near normal renal histology, with marked reduction in glomerular immune deposition and the infiltration by T cells, B cells and macrophages. Rapamycin treatment was associated with down-regulation of intra-renal expression of monocyte chemoattractant protein-1 (MCP-1) mRNA and protein. We conclude that rapamycin is highly effective in preventing the development of nephritis in NZB/W F₁ mice. The beneficial effects of rapamycin are mediated through inhibition of lymphoproliferation and reduced MCP-1 expression.

Keywords

autoimmunity lupus nephritis NZB/W F1 mice rapamycin

Get full access to this article

View all access options for this article.

References

1 D’Cruz DP Khamashta MA Hughes GR . Systemic lupus erythematosus. Lancet 2007; 369: 587 – 596 .

2 Agrawal N Chiang LK Rifkin IR . Lupus nephritis. Semin Nephrol 2006; 26: 95 – 104 .

3 Davidson A Aranow C . Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006; 18: 468 – 475 .

4 Waldman M Appel GB . Update on the treatment of lupus nephritis. Kidney Int 2006; 70: 1403 – 1412 .

5 Kahan BD . Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903 – 1917 .

6 Sehgal SN . Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335 – 340 .

7 MacDonald AS . ; RAPAMUNE Global Study Group.

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.

Transplantation 2001; 71: 271 – 280 .

8 Stallone G Infante B Schena A . Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755 – 3762 .

9 Chen JK Chen J Neilson EG Harris RC . Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005; 16: 1384 – 1391 .

10.

10 Bonegio RG Fuhro R Wang Z . Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063 – 2072 .

11.

11 Wu MJ Wen MC Chiu YT Chiou YY Shu KH Tang MJ . Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69: 2029 – 2036 .

12.

12 Howie JB Helyer BJ . The immunology and pathology of NZB mice. Adv Immunol 1968; 9: 215 – 266 .

13.

13 Dixon FJ Andrews BS Eisenberg RA McConahey PJ Theofilopoulos AN Wilson CB . Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum 1978; 21(Suppl. 5): S64 – S67 .

14.

14 Warner LM Adams LM Sehgal SN . Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37: 289 – 297 .

15.

15 Yung S Woods A Chan TM Davies M Williams JD Couchman JR . Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization. FASEB J 2001; 15: 1631 – 1633 .

16.

16 Zoja C Liu XH Donadelli R . Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997; 8: 720 – 729 .

17.

17 Ramos-Barron A Pinera-Haces C Gomez-Alamillo C . Prevention of murine lupus disease in (NZBXNZW)F1 mice by sirolimus treatment. Lupus 2007; 16: 775 – 781 .

18.

18 Viedt C Orth SR . Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol Dial Transplant 2002; 17: 2043 – 2047 .

19.

19 Viedt C Dechend R Fei J Hansch GM Kreuzer J Orth SR . MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002; 13: 1534 – 1547 .

20.

20 Wolf G Jocks T Zahner G Panzer U Stahl RA . Existence of a regulatory loop between MCP-1 and TGF-beta in glomerular immune injury. Am J Physiol Renal Physiol 2002; 283: F1075 – F1084 .

21.

21 Rovin BH Song H Birmingham DJ Hebert LA Yu CY Nagaraja HN . Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467 – 473 .

22.

22 Hasegawa H Kohno M Sasaki M . Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003; 48: 2555 – 2566 .

23.

23 Anders HJ Vielhauer V Kretzler M . Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol 2001; 12: 919 – 931 .

24.

24 Ma KL Ruan XZ Powis SH Moorhead JF Varghese Z . Anti-atherosclerotic effects of Sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292: H2721 – H2728 .

25.

25 Castro C Campistol JM Sancho D Sanchez-Madrid F Casals E Andres V . Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004; 172: 31 – 38 .

26.

26 Oliveira JG Xavier P Sampaio SM . Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation 2002; 73: 915 – 920 .

27.

27 Chan TM Tse KC Tang CS Mok MY Li FK . : Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076 – 1084 .

28.

28 Corna D Morigi M Facchinetti D Bertani T Zoja C Remuzzi G . Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583 – 1589 .

29.

29 Van Bruggen MC Walgreen B Rijke TP Berden JH . Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407 – 1415 .

30.

30 Chan TM Leung JK Ho SK Yung S . Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 1219 – 1229 .

31.

31 Yung S Tsang RC Sun Y Leung JK Chan TM . Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol 2005; 16: 3281 – 3294 .

32.

32 Schiffer L Sinha J Wang X . Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003; 171: 489 – 497 .

33.

33 Kinoshita K Yoo BS Nozaki Y . Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol 2003; 170: 5793 – 5798 .

34.

34 Zoja C Corna D Rottoli D Zanchi C Abbate M Remuzzi G . Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 2006; 70: 97 – 103 .